ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mielom multiplu - agenți antineoplazici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - dexamethasonum - comprimate - 0,5 mg

মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - dexamethasonum - comprimate - 2 mg

মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - dexamethasonum - comprimate - 4 mg

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

takeda pharma a/s - citrat de ixazomib - mielom multiplu - agenți antineoplazici - ninlaro în asociere cu lenalidomidă și dexametazonă este indicat pentru tratamentul pacienților adulți cu mielom multiplu care au primit cel puțin o terapie anterioară.

মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janssen-cilag international nv - daratumumabum - concentrat pentru soluţie perfuzabilă - 20 mg/ml

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mielom multiplu - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

pharmaand gmbh - panobinostat lactat anhidru - mielom multiplu - agenți antineoplazici - farydak, în combinaţie cu bortezomib şi dexametazona, este indicat pentru tratamentul pacienţilor adulţi cu recăderi și/sau refractare mielom multiplu, care au primit cel puţin două regimuri prealabile inclusiv bortezomib şi un agent imunomodulator. farydak, în combinaţie cu bortezomib şi dexametazona, este indicat pentru tratamentul pacienţilor adulţi cu recăderi și/sau refractare mielom multiplu, care au primit cel puţin două regimuri prealabile inclusiv bortezomib şi un agent imunomodulator.

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - dexamethasonum - compr. - 4mg - corticosteroizi sistemici glucocorticoizi

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - dexamethasonum - compr. - 8mg - corticosteroizi sistemici glucocorticoizi